Allogenic hematopoietic stem-cell transplantation (allo-HSCT) is a widely employed treatment for a broad range of hematological malignancies because of its graft-versus-tumor (GvT) effect. Unfortunately, allo-HSCT is still associated with morbidity and mortality related to relapse and transplant complications, namely graft-versus-host-disease (GvHD). In an era of therapies specifically targeting molecular pathways, transcription factors and cytokines, a better understanding of …